Document is current
Any future updates will be listed below
-
Authors
Kubasch, Anne Sophie http://orcid.org/0000-0002-0747-4941
Giagounidis, Aristoteles
Metzgeroth, Georgia
Jonasova, Anna http://orcid.org/0000-0003-0246-1524
Herbst, Regina
Diaz, Jose Miguel Torregrosa
De Renzis, Benoit
Götze, Katharina S.
Huetter-Kroenke, Marie-Luise
Gourin, Marie-Pierre
Slama, Borhane
Dimicoli-Salazar, Sophie
Cony-Makhoul, Pascale
Laribi, Kamel
Park, Sophie
Jersemann, Katja
Schipp, Dorothea
Metzeler, Klaus H. http://orcid.org/0000-0003-3920-7490
Tiebel, Oliver
Sockel, Katja http://orcid.org/0000-0003-1732-7299
Gloaguen, Silke
Mies, Anna
Chermat, Fatiha
Thiede, Christian
Sapena, Rosa
Schlenk, Richard F. http://orcid.org/0000-0003-2215-2059
Fenaux, Pierre
Platzbecker, Uwe http://orcid.org/0000-0003-1863-3239
Adès, Lionel http://orcid.org/0000-0002-9020-8766
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 18 February 2022
Revised: 18 June 2022
Accepted: 25 July 2022
First Online: 7 September 2022
Competing interests
: The EUROPE study was partially supported by Amgen GmbH. UP, Research funding: Janssen Pharmaceuticals. Consultancy and Honoraria: Novartis, Abbvie, Celgene. AG, Research funding: Janssen Pharmaceuticals. PF: Research funding: Janssen Pharmaceuticals. RS, Honoraria and Research Funding: Teva Pharmaceutical Industries. CT, Employment and Equity Ownership: AgenDix GmbH, Consultancy, Honoraria, Research Funding and Speakers Bureau: Novartis, Honararia: Daiichi Sankyo. LA: Research funding: Janssen Pharmaceuticals. Consultancy and Honoraria: Celgene, Novartis, Takeda Jazz, Abbvie. ASK: Research funding: Janssen Pharmaceuticals. Consultancy and Honoraria: Novartis, Janssen Pharmaceuticals., Takeda. The other authors declare no relevant conflicts of interests.
